Iain McInnes
www.gla.ac.uk
0000-0003-4449-8501
6 papers found
Refreshing results…
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis
Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research
Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis
Missing publications? Search for publications with a matching author name.